Stock listing
Cel-sci Corporation
Selected listing: LSR · FWB · EUR · DE
Cel-sci Corporation (Frankfurt:LSR), Health Technology. Latest release Aug 17, 2026: CEL-SCI Reports Fiscal Third Quarter 2026 Results.
- Ticker
- Frankfurt:LSR
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
About Cel-sci Corporation
The company is focused on developing innovative therapies for cancer and other diseases. Its commitment to advancing healthcare solutions positions it as a notable player in the biotechnology sector.
Latest news from Cel-sci Corporation
CEL-SCI Reports Fiscal Third Quarter 2026 Results
August 17, 2026
Cel-Sci: Fiscal Q3 Earnings Snapshot
August 14, 2026
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
July 13, 2026
CEL-SCI Announces Closing of Offering
June 16, 2026
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
June 16, 2026
Research Cel-sci Corporation
Alternate listings
CVM:AMEX
US · USD
Alternate listing for Cel-sci Corporation; the primary context on this page is LSR:FWB.
LSR:GETTEX
DE · EUR
Alternate listing for Cel-sci Corporation; the primary context on this page is LSR:FWB.
CVM:BOATS
US · USD
Alternate listing for Cel-sci Corporation; the primary context on this page is LSR:FWB.
LSR:MUN
DE · EUR
Alternate listing for Cel-sci Corporation; the primary context on this page is LSR:FWB.
A418TV:LS
DE · EUR
Alternate listing for Cel-sci Corporation; the primary context on this page is LSR:FWB.
A418TV:LSX
DE · EUR
Alternate listing for Cel-sci Corporation; the primary context on this page is LSR:FWB.